Umbilical cord mesenchymal stem cells for COVID‐19 acute respiratory distress syndrome: A double‐blind, phase 1/2a, randomized controlled trial

Umbilical cord mesenchymal stem cells for COVID‐19 acute respiratory distress syndrome: A double‐blind, phase 1/2a, randomized controlled trial

Abstract Acute respiratory distress syndrome (ARDS) in COVID‐19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti‐inflammatory effects and could yield beneficial effects in COVID‐19 ARDS. The objective of this study was to determine safety and exp...

Full description

Bibliographic Details
Main Authors: Giacomo Lanzoni, Elina Linetsky, Diego Correa, Shari Messinger Cayetano, Roger A. Alvarez, Dimitrios Kouroupis, Ana Alvarez Gil, Raffaella Poggioli, Phillip Ruiz, Antonio C. Marttos, Khemraj Hirani, Crystal A. Bell, Halina Kusack, Lisa Rafkin, David Baidal, Andrew Pastewski, Kunal Gawri, Clarissa Leñero, Alejandro M. A. Mantero, Sarah W. Metalonis, Xiaojing Wang, Luis Roque, Burlett Masters, Norma S. Kenyon, Enrique Ginzburg, Xiumin Xu, Jianming Tan, Arnold I. Caplan, Marilyn K. Glassberg, Rodolfo Alejandro, Camillo Ricordi
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Stem Cells Translational Medicine
Subjects:
cell transplantation
cellular therapy
clinical trials
mesenchymal stem cells
respiratory tract
transplantation
Online Access:https://doi.org/10.1002/sctm.20-0472

Internet

https://doi.org/10.1002/sctm.20-0472

Similar Items